title: Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
authors.affiliation: Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.|University of Queensland, Brisbane, Qld, Australia.|QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.
authors.forename: G L
authors.initials: GL
authors.lastname: Radford-Smith
authors.affiliation: Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.
authors.forename: F
authors.initials: F
authors.lastname: Hartnell
authors.affiliation: CSIRO Preventative Health Flagship, Parkville, Vic., Australia.|CSIRO Computational Informatics/Australian e-Health Research Centre, Brisbane, Qld, Australia.
authors.forename: J D
authors.initials: JD
authors.lastname: Doecke
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001315:Australia; D003424:Crohn Disease; D006801:Humans; D000069285:Infliximab; D009520:New Zealand
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab